Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
beclomethasone + formoterol + glycopyrronium
- Development stage
- Approved
- Lead developer
- Chiesi
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Trimbow is a fixed-dose triple combination therapy containing an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA). Specifically, it consists of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide. Developed by Chiesi Farmaceutici and licensed to partners like Kolon Pharma in South Korea, it is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma in adults. The formulation is designed to improve lung function and reduce exacerbations by providing anti-inflammatory action, bronchodilation, and inhibition of acetylcholine-induced bronchoconstriction. It is available as a pressurized metered-dose inhaler (pMDI) and a dry powder inhaler (Nexthaler).
- Brand names
- Trimbow
- Other names
- beclomethasone dipropionate + formoterol fumarate + glycopyrronium bromideTrimbow NexthalerTrimbow pMDI HS
02
Targets
ADRB2 (β2)GR (Glucocorticoid receptor)CHRM3 (M3)
Beyond the preview
Go deeper on beclomethasone + formoterol + glycopyrronium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on beclomethasone + formoterol + glycopyrronium.